HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Portfolio Tracker
Get an update on your stocks every day. See earnings revisions, new reports and Zacks Rank changes at a glance. Click here to learn more.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

Gentiva Beats Zacks Estimate

By: Zacks Equity Research
October 29, 2009 | Comments: 0
Recommended this article (1)
Print    Share

Gentiva Health Services Inc. (GTIV - Analyst Report) reported a third-quarter (ended Sept. 27, 2009) net income of 54 cents per share, which beat the Zacks Consensus Estimate by 2 cents. Net income per share was 42 cents in the year-ago quarter.

Net revenues for the quarter came in at $295.6 million, as against $345.2 million in the year-ago quarter. Revenues for the reported quarter included net revenues of $75.5 million from the CareCentrix business unit. Excluding the 2008 third quarter net revenues from CareCentrix, Gentiva's net revenues increased about 9% in the reported quarter. On Sept. 25, 2008, Gentiva sold a majority interest in CareCentrix to Water Street Healthcare Partners.

Revenues from the Home Health segment increased 9% to $261.4 million in the reported quarter. Revenues in the All Other segment - which includes hospice, respiratory therapy and home medical equipment, infusion therapy and consulting - came in at $34.6 million, which reflected an increase of 11%.

Selling, general and administrative expenses fell to $126.62 million from $127.9 million in the year-ago quarter. Gentiva exited the quarter with cash, cash equivalents and short-term investments of approximately $125.3 million as against $69.2 million at the end of 2008.

Gentiva has reaffirmed its guidance for the full-year 2009. The company expects 2009 net revenues to come between $1.19 billion to $1.21 billion. The company expects 2009 earnings in the range of $2.04 to $2.10.

Headquartered in Atlanta, GA, Gentiva boasts of a diversified product portfolio. Its product offerings include home health, hospice, respiratory therapies and home medical equipment. The company serves nearly 500,000 patients annually in more than 380 locations across 39 states.

Gentiva has successfully grown through acquisitions. During the past few years, the company has completed multiple acquisitions which have expanded its reach. The company is still on the lookout for other profitable buys. It competes with players such as American Homepatient Inc., Amedisys Inc. (AMED - Snapshot Report) and the privately held Apria Healthcare Group Inc.

We have an Outperform rating on the stock.

Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Free Stock Analysis From Zacks
  Includes Zacks Long-Term Recommendation and Target Price
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Feb 10, 2010 02:27 am ET
DJIA 10058.64  150.25 1.52%
NASD 2150.87  0.00 0.00%
S&P 500 1070.52  13.78 1.30%